Leukemia-Lymphoma Society Is Encouraged By Promising News For Myeloma Patients
Millennium Pharmaceuticals and Johnson & Johnson have reported that an interim analysis of a large, randomized, international Phase III trial comparing melphalan-prednisone (MP) with MP in combination with Velcade (bortezomib) showed that the patients treated on the Velcade arm did better.
These patients, who are not eligible for a stem cell transplant, experienced statistically significant benefit in terms of time-to-disease progression, complete response rate, progression-free survival and overall survival. Patients treated on the MP arm of the trial have the opportunity to switch over to the Velcade arm.
Detailed results from this trial will be presented at the American Society of Hematology annual meeting in early December.
"This is extremely encouraging news for myeloma patients," said Bart Kamen, M.D., Ph.D., the Society's chief medical officer. "However, while these results are very exciting, the Society reminds patients not to make any changes in their treatment regimen without speaking to their doctor first."